ArticleMolecular cancer therapeutics2025

The Anti-FRα Antibody-Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non-Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death.

Robert Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.